Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
First human trial of cellular rejuvenation therapy begins after two decades of research

First human trial of cellular rejuvenation therapy begins after two decades of research

New Capabilities

Life Biosciences tests whether partially resetting the epigenetic clock can restore vision in glaucoma patients

April 9th, 2026: Nature highlights first human cellular rejuvenation trial

Overview

In 2006, Shinya Yamanaka showed that four genes could rewind an adult cell all the way back to an embryonic-like state. Twenty years later, a stripped-down version of that technique is being injected into human eyes for the first time. Life Biosciences, a Boston biotech co-founded by Harvard aging researcher David Sinclair, has begun dosing glaucoma patients with ER-100, a gene therapy that delivers three of Yamanaka's four reprogramming factors to retinal cells — with a built-in off switch controlled by the common antibiotic doxycycline.

The Phase 1 trial, cleared by the Food and Drug Administration (FDA) in January 2026 and featured in Nature's April 9 issue, tests whether partially dialing back a cell's biological clock can restore function in damaged human tissue without triggering dangerous side effects like tumor growth. If the therapy works, it would validate a radically new approach to medicine: not just treating disease, but reversing the cellular aging that causes it. Billions of dollars and a new generation of biotech companies are riding on the answer.

Why it matters

If resetting a cell's age can restore lost vision, the same approach could eventually target heart disease, neurodegeneration, and aging itself.

Play on this story Voices Debate Predict

Key Indicators

1st
First human trial of epigenetic reprogramming
ER-100 is the first cellular rejuvenation therapy to receive FDA clearance for testing in humans.
3
Yamanaka factors used (of four)
The fourth factor, c-Myc, was excluded because it is associated with cancer.
$80M
Series D funding closed April 8, 2026
Funds the trial through completion and advances Life Biosciences' broader reprogramming platform.
20 years
From discovery to human trial
Yamanaka published the foundational induced pluripotent stem cell research in 2006.
$6B+
Estimated capital invested across reprogramming field
Altos Labs alone launched with roughly $3 billion; dozens of startups have raised additional billions.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

David A. Sinclair
David A. Sinclair
Leading the scientific vision behind the first human reprogramming trial
 Jerry McLaughlin
Jerry McLaughlin
Leading company through its first clinical trial and $80M Series D raise
 Shinya Yamanaka
Shinya Yamanaka
Director Emeritus, Center for iPS Cell Research and Application (CiRA), Kyoto University; Senior Investigator, Gladstone Institutes

Organizations Involved

Life Biosciences
Life Biosciences
Clinical-stage biotechnology company
Conducting the first-ever human trial of cellular rejuvenation therapy

Boston-based biotech developing partial epigenetic reprogramming therapies to reverse aging-related diseases.
Altos Labs
Altos Labs
Biotechnology research company
Began early human safety testing in August 2025; transitioning toward clinical stage

The best-funded company in cellular reprogramming, backed by roughly $3 billion from investors including Jeff Bezos and Yuri Milner.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Cleared the first human trial of epigenetic reprogramming therapy

The United States agency responsible for approving drugs, biologics, and gene therapies for human use.

Timeline

August 2006 April 2026

12 events Latest: April 9th, 2026 · 1 month ago Showing 8 of 12
Tap a bar to jump to that date

  1. Nature highlights first human cellular rejuvenation trial

    Latest Publication

    Nature's April 9 issue features the launch of the ER-100 trial as a landmark moment for longevity medicine, with accompanying analysis in Nature Biotechnology examining the science and regulatory significance.

  2. Life Biosciences closes $80 million Series D

    Corporate

    Life Biosciences closes a fully subscribed $80 million Series D round to fund the ER-100 trial through completion and advance its broader reprogramming platform into additional indications.

  3. FDA clears first human trial of cellular rejuvenation

    Regulatory

    The FDA clears Life Biosciences' Investigational New Drug application for ER-100, making it the first epigenetic reprogramming therapy authorized for testing in humans. The Phase 1 trial will enroll patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

  4. Life Biosciences presents preclinical data at ARDD 2025

    Scientific Presentation

    Life Biosciences presents new data on its Partial Epigenetic Reprogramming platform in liver and ocular diseases at the Aging Research and Drug Discovery conference.

  5. Sinclair publishes epigenetic information theory of aging

    Scientific Discovery

    Sinclair's lab publishes in Cell providing evidence that aging is driven by the loss of epigenetic information, not just genetic mutations, and that this process is reversible.

  6. Altos Labs launches with $3 billion

    Corporate

    Altos Labs launches as the best-funded company in the reprogramming field, backed by Jeff Bezos and Yuri Milner, recruiting top scientists including Yamanaka as an advisor.

  7. Sinclair lab restores vision in blind mice via epigenetic reprogramming

    Scientific Discovery

    David Sinclair's lab publishes in Nature showing that delivering three Yamanaka factors (Oct4, Sox2, Klf4) to retinal ganglion cells reverses vision loss in mice with glaucoma and in aged mice — the foundational proof-of-concept for ER-100.

  8. FDA approves Luxturna, first ocular gene therapy

    Regulatory

    The FDA approves Spark Therapeutics' Luxturna (voretigene neparvovec) for inherited retinal dystrophy, establishing a regulatory precedent for delivering gene therapies directly into the eye.

  9. Life Biosciences founded

    Corporate

    David Sinclair co-founds Life Biosciences in Boston to develop therapies targeting the mechanisms of aging, initially as a holding company with multiple subsidiaries.

  10. First in vivo partial reprogramming extends lifespan in mice

    Scientific Discovery

    Juan Carlos Izpisua Belmonte's lab at the Salk Institute publishes in Cell showing that cyclic, short-term expression of Yamanaka factors extends lifespan in a mouse model of premature aging — the first proof that partial reprogramming works in living animals.

  11. Yamanaka awarded Nobel Prize

    Recognition

    Shinya Yamanaka and Sir John Gurdon share the Nobel Prize in Physiology or Medicine for demonstrating that mature cells can be reprogrammed to a pluripotent state.

  12. Yamanaka publishes iPSC discovery

    Scientific Discovery

    Shinya Yamanaka and Kazutoshi Takahashi publish in Cell showing that four genes — Oct4, Sox2, Klf4, and c-Myc — can reprogram adult mouse cells into an embryonic-like pluripotent state.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2017

Luxturna: First ocular gene therapy (2017)

Spark Therapeutics won FDA approval for Luxturna (voretigene neparvovec), a gene therapy injected directly into the eye to treat an inherited form of blindness caused by mutations in the RPE65 gene. In the pivotal trial, 27 of 29 patients experienced improved sight. The advisory committee voted 16-0 in favor of approval.

Then

Luxturna launched at a price of $850,000 per patient, sparking debate about gene therapy pricing. It demonstrated that the eye is a viable and relatively safe compartment for gene therapy delivery.

Now

Luxturna established the regulatory template for ocular gene therapies, creating the pathway that Life Biosciences followed to get ER-100 into human trials. It proved that a single injection could produce lasting therapeutic benefit in a confined organ.

Why this matters now

ER-100 uses the same basic delivery approach — an adeno-associated virus injected into the eye — and benefits directly from the safety and regulatory precedent Luxturna established. The eye's immune-privileged status and small volume make it the safest starting point for a novel gene therapy.

September 1999

Jesse Gelsinger gene therapy death (1999)

Jesse Gelsinger, an 18-year-old with a mild liver disorder called ornithine transcarbamylase deficiency, died four days after receiving an experimental adenoviral gene therapy at the University of Pennsylvania. His immune system mounted an overwhelming inflammatory response to the viral vector. Investigations revealed undisclosed safety problems in earlier patients and conflicts of interest among the researchers.

Then

The FDA halted multiple gene therapy trials nationwide. The principal investigator, James Wilson, was barred from conducting FDA-regulated research for five years. Public trust in gene therapy collapsed.

Now

The field pivoted to safer adeno-associated virus (AAV) vectors instead of adenoviruses, developed more rigorous safety monitoring protocols, and took nearly two decades to recover. The caution instilled by this case shaped every subsequent gene therapy trial design, including ER-100's.

Why this matters now

The Gelsinger case is the cautionary backdrop for every first-in-human gene therapy trial. Life Biosciences' decision to target the eye — a small, enclosed organ where damage stays localized — and to include a doxycycline safety switch reflects lessons learned from this tragedy. Any serious adverse event in the ER-100 trial would be measured against this precedent.

2019-2023

CRISPR gene editing reaches the clinic (2019-2023)

The first CRISPR-based gene editing therapy entered human trials in 2019. After four years of clinical testing, the FDA approved Casgevy (exagamglogene autotemcel) in December 2023 for sickle cell disease — the first CRISPR therapy to receive regulatory approval anywhere. The arc from Emmanuelle Charpentier and Jennifer Doudna's foundational 2012 paper to approval took 11 years.

Then

Casgevy's approval validated CRISPR as a clinical tool and opened a wave of gene editing therapies for blood disorders, cancer, and inherited diseases.

Now

CRISPR therapies are now in dozens of clinical trials across multiple disease areas, with the technology becoming increasingly precise and versatile.

Why this matters now

The CRISPR arc — from Nobel-winning basic science to clinical approval in roughly a decade — offers the most direct parallel for where epigenetic reprogramming stands today. Life Biosciences' ER-100 trial is the equivalent of CRISPR's first human tests: the moment a transformative laboratory technique begins proving itself in patients.

Sources

(11)
+5
Nature Life Biosciences MIT Technology Review Fortune BioSpace ClinicalTrials.gov Lifespan.io Longevity Technology Nature Biotechnology Nature Nature